Top

Published in:

01-08-2014 | Original Article

Mesenchymal stromal cells versus betamethasone can dampen disease activity in the collagen arthritis mouse model

Authors: E. S. M. El-denshary, L. A. Rashed, M. Elhussiny

Published in: Clinical and Experimental Medicine | Issue 3/2014

Abstract

The objective of this study was to compare between the effects of mesenchymal stem cell (MSC) and betamethasone in the treatment of rheumatoid arthritis. Sixty male albino mice were divided equally into 2 models. They are MSC model, group 1: saline control group, group 2: collagen-induced arthritis (CIA), group 3: induced arthritis mice that received intravenous injection of MSCs. Betamethasone model, group 1: phosphate buffer saline, group 2: CIA, group 3: induced arthritis mice that received intraperitoneal injection of betamethasone. Mice arthritis models were assessed by clinical paw edema and X-rays, at the proper time of sacrefaction, tissues were collected and examined using real-time PCR, and synovial tissue was examined for interleukin-10, tumor necrosis factor α, cartilage oligomeric matrix protein and matrix metalloproteinase 3. While serum levels of rheumatoid factor and C-reactive protein were detected by enzyme-linked immunosorbent assay kits. Also blood erythrocyte sedimentation rate was detected. Histopathological, paw edema and PCR results showed improvement in the groups that received MSC compared with the diseased group and the groups which received betamethasone. MSC significantly enhanced the effect of collagen-induced arthritis treatment, which is superior to betamethasone treatment, likely through the modulation of the expression of various cytokines.

Abdel Aziz MT, Atta H, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Hassouna AA, Hassan NM (2007) Therapeutic potential of bone marrow-derived mesenchymal stromal cells on experimental liver cirrhosis. Clin Biochem 40:893–899PubMedCrossRef

Andrea A, Roberta T, Simone M, Ranieri C, Giuseppina P (2007) Cell therapy using allogeneic bone marrow mesenchymal stromal cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56:1175–1186CrossRef

Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms [review]. Clin Sci (Lond) 94:557–572

Buttgereit F, Wehling M, Burmester GR (1998) A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited [current comment]. Arthritis Rheumatol 41:761–767CrossRef

Clapp C, Thebault S, Michael CJ, De la Escalera GM (2009) Peptide hormone regulation of angiogenesis. Physiol Rev 89(4):1177–1215PubMedCrossRef

Crawford WH, Houge JC, Neirby DT, Di Mino A, Di Mino AA (1991) Pulsed radio frequency therapy of experimentally induced arthritis in ponies. Can J Vet Res 55:76–85PubMedCentralPubMed

Djouad F, Bony C, Haupl T, Uze G, Lahlou N, Louis-Plence P, Apparailly F, Canovas F, Reme T, Sany J (2005) Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther 7:R1304–R1315

Fox DA (1997) The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 40:598–609

Ganesan K, Tiwari M, Balachandran C, Manohar BM, Puvanakrishnan R (2008) Estrogen and testosterone attenuate extracellular matrix loss in collagen-induced arthritis in rats. Calcif Tissue Int 83:354–364PubMedCrossRef

10.

Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noël D (2010) Immuno-suppression by mesenchymal stromal cells: mechanisms and clinical applications. Stem Cell Res Ther 1(1):2PubMedCentralPubMedCrossRef

11.

Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152:943–951PubMedCentralPubMed

12.

Grigolo B, Lisignoli G, Desando G, Cavallo C, Marconi E, Tschon M, Giavaresi G, Fini M, Giardino R, Facchini A (2009) Osteoarthritis treated with mesenchymal stem cells on hyaluronan-based scaffold in rabbit. Tissue Eng Part C Methods 15(4):647–658PubMedCrossRef

13.

Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389:737–742PubMedCrossRef

14.

Higaki M, Ishihara T, Izumo N, Takatsu M, Mizushima Y (2005) Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann Rheum Dis 64(8):1132–1136PubMedCentralPubMedCrossRef

15.

Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ (1998) Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95:365–377PubMedCrossRef

16.

Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, Granger EL, Norbury CC, Hauschka SD, Philbrick WM, Lee CG, Elias JA, Kim JK (2009) Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 58:2525–2535PubMedCentralPubMedCrossRef

17.

Ishihara T, Kubota T, Choi T, Higaki M (2009) Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J Pharmacol Exp Ther 329(2):412–417PubMedCrossRef

18.

Johnson LL, Dyer R, Hupe DJ (1998) Matrix metalloproteinases. Curr Opin Chem Biol 2:466–471PubMedCrossRef

19.

Kim WU, Kim KJ (2005) T cell proliferative response to type II collagen in the inflammatory process and joint damage in patients with rheumatoid arthritis. J Rheumatol 32:225–230PubMed

20.

Kokebie R, Aggarwal R, Lidder S, Hakimiyan AA, Rueger DC, Block JA, Chubinskaya S (2011) The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. Arthritis Res Ther 13(2):R50PubMedCentralPubMedCrossRef

21.

Larsson E, Harris HE, Larsson A, Månsson B, Saxne T, Klareskog L (2003) Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatology 43:428–434CrossRef

22.

Liu Y, Mu R, Wang S, Long L, Liu X, Li R, Sun J, Guo J, Zhang X, Guo J, Yu P, Li C, Liu X, Huang Z, Wang D, Li H, Gu Z, Liu B, Li Z (2010) Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 12(6):R210PubMedCentralPubMedCrossRef

23.

Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D (2005) Interaction of human mesenchymal stromal cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90:516–525PubMed

24.

Maldonado A, Mueller YM, Thomas P, Bojczuk P, O’Connors C, Katsikis PD (2003) Decreased effector memory CD45RA+ CD62L CD8+ T cells and increased central memory CD45RA-CD62L+ CD8+ T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res Ther 5:R91–R96PubMedCentralPubMedCrossRef

25.

Min SY, Park KS, Cho ML, Kang JW, Cho YG, Hwang SY (2006) Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer’s patches during the induction of oral tolerance to type II collagen and suppress experimental collagen induced arthritis. Arthritis Rheum 54:887–898PubMedCrossRef

26.

Ngian GS (2010) Rheumatoid arthritis. Aust Fam Physician 39(9):626–628PubMed

27.

Park J, Lappe M, Teichmann A (2001) Mapping protein family interactions: intramolecular and intermolecular protein family interaction repertoires in the PDB and yeast. J Mol Biol 307:929–938

28.

Ram S, Blumberg D, Newton B, Anderson N, Gama R (2004) Raised serum CRP in rheumatoid arthritis: genuine or laboratory artifact? Rheumatology 43:1272–1274PubMedCrossRef

29.

Salamon A, Toldy E (2009) Adult bone marrow derived mesenchymal stem cells as stem cells for tissue repair. CEMED 3:369–379

30.

Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H (2008) Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 180:2581–2587PubMedCrossRef

31.

Sekine T, Kato T, Masuko-Hongo K, Nakamura H, Yoshino S, Nishioka K (1999) Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 58:446–450PubMedCentralPubMedCrossRef

32.

Ståhle-Bäckdahl M, Sandstedt B, Bruce K, Lindahl A, Jimenez MG, Vega JA, Lopez-Otin C (1997) Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in post-natal bone remodeling and in rheumatoid arthritis. Lab Invest 76:717–728PubMed

33.

Suzuki Y, Nishikaku F, Nakatuka M, Koga Y (1998) Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol 25:1154–1160PubMed

34.

Torsteinsdóttir I, Hâkansson L, Hällgren R, Gudbjörnsson B, Arvidson NG, Venge P (1999) Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxf) 38(12):1249–1254CrossRef

35.

Tseng S, Reddi AH, Di Cesare PE (2009) Cartilage oligomeric matrix protein (COMP): a biomarker of arthritis. Biomark Insights 4:33–44PubMedCentralPubMed

36.

Werb Z (1997) ECM and cell surface proteolysis regulating cellular ecology. Cell 91:439–442PubMedCrossRef

37.

Zhang M, Mal N, Kiedrowsk M, Chacko M, Askari AT, Popovic ZB, Koc ON, Penn MS (2007) SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 21:3197–3207PubMedCrossRef

38.

Zheng SG, Wang J, Horwitz DA (2008) Cutting edge: Foxp3+ CD4+ CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 180(11):7112–7116PubMedCrossRef

39.

Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y (2008) Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 5:417–424PubMedCentralPubMedCrossRef

Title: Mesenchymal stromal cells versus betamethasone can dampen disease activity in the collagen arthritis mouse model
Authors: E. S. M. El-denshary
L. A. Rashed
M. Elhussiny
Publication date: 01-08-2014
Publisher: Springer Milan
Published in: Clinical and Experimental Medicine / Issue 3/2014
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-013-0248-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Role of mesenchymal stem cells in leukaemia: Dr. Jekyll or Mr. Hyde?

Apocynin regulates cytokine production of CD8+ T cells

Decreased ITGAM and FcγRIIIA mRNA expression levels in peripheral blood mononuclear cells from patients with systemic lupus erythematosus

Programmed death-1 (PD-1)-dependent functional impairment of CD4+ T cells in recurrent genital papilloma

The diagnostic value of monoclonal gastric cancer 7 antigen: a systematic review with meta-analysis

An eight-colour flow cytometric method for the detection of reference values of lymphocyte subsets in selected healthy donors

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials